Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers’ program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
Pfizer Inc., the world’s largest drug maker, will pay a record $2.3 billion civil and criminal penalty over unlawful prescription
drug promotions, the Justice Department announced today.
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.
The Indianapolis-based forensics, clinical and pharmaceutical testing firm now ranks 598, up from 1,466 a year ago. The list
is based on percentage of revenue growth.
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But
Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first
quarter.
The CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company’s fast-growing DailyMed
service.
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
